INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo CALSUBA® Calcium Tablets
SCHEDULING STATUS:
Not Scheduled

PROPRIETARY NAME
(and dosage form):

CALSUBA® Calcium Tablets

COMPOSITION:
Each tablet contains:
Calcium Carbonate        500,0 mg

PHARMACOLOGICAL CLASSIFICATION:
A24: Mineral substitutes, electrolytes.

PHARMACOLOGICAL ACTION:
Calcium supplement.

INDICATIONS:
Supplement where a calcium deficiency exists.

CONTRA-INDICATIONS:
Hypercakaemia resulting from eg. hyperparathyroidism and excess intake of Vitamin D, neoplastic disease, hyperthyroidism, milk-alkali syndrome. Acidosis because of increased ionisation of calcium.

DOSAGE AND DIRECTIONS FOR USE:
Adults:
        Chew one to two tablets three times daily with meals.
Children over 6 years of age:
        Chew half to one tablet three times daily with meals.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
May cause gastro-intestinal irritation and constipation. Hypercalcaemia can occur as can alkalosis following the regular use of calcium carbonate. Calcium salts should be given cautiously to patients with impaired renal function or a history of renal stone formation. Should also be given with caution to patients with cardiac disease or sarcoidosis.

Calcium enhances the effects of digitalis on the heart and may precipitate digitalis intoxication. Calcium salts reduce the absorption of tetracyclines.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Excessive administration of calcium salts may lead to hypercalcaemia which may include anorexia nausea, vomiting, constipation, abdominal pain, muscle weakness, mental disturbances, polydipsia, polyuria, bone pain, nephrocalcinosis, renal calculi and in severe cases cardiac arrhythmias and coma.
Treatment is symptomatic and supportive.

IDENTIFICATION:
An orange coloured bevelled edge tablet.

PRESENTATION:
“Securitainers”of 50 tablets.

STORAGE INSTRUCTIONS:
Keep in a cool (below 25°C) dry place. Replace lid securely after use.
Keep out of reach of children.

REGISTRATION NUMBER:
Y/24/33

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Group Laboratories SA (Pty) Limited
39 Hawkins Avenue, Epping Industria 1
Cape Town, 7460

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
July 1991

Distributed by: SmithKline Beecham Consumer Healthcare for:

Group Laboratories SA (Pty) Ltd.        Rosside 20793
                        P2320

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2003